Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in relapsed/refractory Waldenström macroglobulinemia
NCT03679455Phase 2Unknown
- Sponsor
- Polish Myeloma Consortium
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in Waldenström macroglobulinemia (WM), sponsored by Polish Myeloma Consortium. Status: unknown.
02
Drugs
obinutuzumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03679455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679455.